VANDA PHARMACEUTICALS INC. financials

VNDA CIK 0001347178

Source: EDGAR filings · Built 2026-06-02T04:19:30Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -112.43M -16.40M 12.42M 31.30M 63.66M 49.98M
EBITDA -143.06M -32.53M -10.94M 9.06M 45.01M 30.10M
Working Capital 202.10M 338.91M 345.25M 427.86M 403.88M 343.21M
Net Debt -72.23M -89.96M -126.42M -123.89M -39.70M -47.42M
Gross Margin 24.53%
Operating Margin -69.95% -20.46% -7.24% 2.49% 15.69% 10.98%
Net Margin -102.02% -9.51% 1.30% 2.47% 12.34% 9.40%
Return on Equity (ROE) -67.38% -3.51% 0.46% 1.19% 6.57% 5.15%
Return on Assets (ROA) -45.09% -2.88% 0.39% 0.99% 5.58% 4.37%
Current Ratio 2.39× 4.39× 4.94× 5.68× 6.43× 6.21×
Debt-to-Equity 0.04× 0.02× 0.02× 0.02× 0.02× 0.03×
Effective Tax Rate -59.02% 17.54% 60.42% 44.47% 21.74% 26.28%
Cash Conversion Ratio 0.50× 0.83× 5.10× 5.10× 1.94× 2.22×
Accruals Ratio -0.23× -0.00× -0.02× -0.04× -0.05× -0.05×
SBC % of Revenue 4.38% 6.25% 7.29% 6.40% 5.72% 5.38%
CapEx Coverage -36.61× -24.43× 33.42× 47.10× 116.33× 28.84×
Free Cash Flow Per Share $-1.91 $-0.28 $0.22 $0.55 $1.12 $0.91

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 105.50× 67.18× 27.05× 31.29×
P/FCF 19.56× 13.45× 14.03× 14.51×
FCF Yield 5.11% 7.43% 7.13% 6.89%
EV / EBITDA 32.64× 18.61× 22.37×
P/S 2.41× 1.41× 1.26× 1.65× 3.26× 2.90×
P/B 1.59× 0.52× 0.45× 0.80× 1.74× 1.59×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 216.10M 198.77M 192.64M 254.38M 268.68M 248.17M
Revenues 216.10M 198.77M 192.64M 254.38M 268.68M 248.17M
Gross Profit 60.87M
Research and Development Expense 109.27M 74.43M 76.82M 85.77M 75.36M 55.58M
Selling, General and Administrative Expense 237.95M 146.41M 112.88M 136.49M 124.05M 140.51M
Operating Income (Loss) -151.17M -40.66M -13.95M 6.33M 42.16M 27.24M
Income Tax Expense (Benefit) 81.83M -4.02M 3.83M 5.03M 9.21M 8.32M
Net Income (Loss) Attributable to Parent -220.47M -18.90M 2.51M 6.28M 33.15M 23.34M
Earnings Per Share, Basic $-3.74 $-0.33 $0.04 $0.11 $0.60 $0.43
Weighted Average Number of Shares Outstanding, Basic 58.93M 58.15M 57.38M 56.46M 55.55M 54.43M
Earnings Per Share, Diluted $-3.74 $-0.33 $0.04 $0.11 $0.58 $0.42
Weighted Average Number of Shares Outstanding, Diluted 58.93M 58.15M 57.56M 56.98M 56.92M 55.19M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 84.85M 102.32M 135.82M 135.03M 52.07M 61.03M
Assets, Current 347.26M 438.89M 432.95M 519.29M 478.30M 409.14M
Assets 488.95M 656.20M 648.44M 634.25M 593.79M 533.46M
Liabilities, Current 145.16M 99.98M 87.70M 91.44M 74.42M 65.94M
Liabilities 161.76M 117.66M 103.53M 107.05M 88.86M 80.19M
Stockholders' Equity Attributable to Parent 327.19M 538.55M 544.91M 527.20M 504.93M 453.27M
Common Stock, Shares, Outstanding 59.10M 58.31M 57.53M 56.78M 55.90M 54.87M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -109.44M -15.76M 12.80M 31.98M 64.21M 51.77M
Payments to Acquire Property, Plant, and Equipment 998.00K 490.00K 383.00K 679.00K 552.00K 1.79M
Net Cash Provided by (Used in) Investing Activities 94.86M -17.43M -12.06M 49.92M -76.70M -41.50M
Net Cash Provided by (Used in) Financing Activities -2.91M -155.00K 0 734.00K 3.55M 5.63M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (VNDA CIK 0001347178), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CRMD

CORMEDIX INC.

MCW

Mister Car Wash, Inc.

TROW

PRICE T ROWE GROUP INC